SENSOCURE RECEIVES CE-MARKING FOR ISCALERT™
The Sensocure team celebrating the CE marking of IscAlert™
PRESS RELEASE – SENSOCURE RECEIVES CE-MARKING FOR ISCALERT
Sensocure Receives CE Marking for the IscAlert™ sensor system: A Groundbreaking Solution for Real-Time Detection of Partial Pressure Carbon Dioxide (PCO2), a conclusive Biomarker for Ischemia.
Sensocure, a pioneering medical technology company, proudly announces the attainment of CE marking for its flagship product, IscAlert™. This significant milestone signifies the compliance of IscAlert™ with the comprehensive regulatory requirements outlined in the European Medical Device Regulation (MDR) 2017/745.
"We are thrilled to achieve CE marking for the IscAlert™ sensor system, validating its efficacy and safety in improving patient care," said Trond Herje, CEO of Sensocure. "IscAlert™ monitors the tissue pCO2, a parameter which increases significantly during the early and reversible stages of ischemia. Monitoring of local tissue pCO2 provides the ability to identify the onset of ischemic events before irreversible injury occurs".
IscAlert™ represents a paradigm shift in medical monitoring technology, offering healthcare professionals a user-friendly, fast, and accurate solution for the measuring of the partial gas pressure of carbon dioxide (pCO2). By measuring the partial gas pressure of carbon dioxide (pCO2) in tissue local to sensor placement, IscAlert™ provides real-time insights, enabling timely intervention to prevent organ injury.
Ischemia, a condition characterized by inadequate blood supply to tissues, poses a significant challenge in clinical practice due to the lack of effective early detection methods. Conventional monitoring solutions often fall short, leading to delayed diagnosis and suboptimal patient outcomes.
The benefits of IscAlert™ extend beyond clinical efficacy, as it seamlessly integrates into existing medical practices, enhancing patient outcomes with the possibility to reduce healthcare costs.
Sensocure remains committed to advancing medical technology and improving patient care through innovation. With the attainment of CE marking for IscAlert™, Sensocure looks forward to expanding access to this groundbreaking solution across healthcare systems worldwide.
For more information about IscAlert™ and Sensocure's innovative biomedical technologies, please visit www.sensocure.no.
About Sensocure:
Sensocure is a leading medical technology company dedicated to developing innovative solutions for early disease detection and patient monitoring. With a focus on improving clinical outcomes and enhancing healthcare efficiency, Sensocure leverages cutting-edge research and advanced engineering to deliver groundbreaking medical devices.